Health Care [ 9/12 ] | Biotechnology [ 36/73 ]
NASDAQ | Common Stock
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.
The company was founded in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -0.32 Increased by +27.27% | -0.26 Decreased by -23.08% |
| May 12, 25 | -0.26 Increased by +45.83% | -0.29 Increased by +11.35% |
| Mar 24, 25 | -0.30 Increased by +46.49% | -0.38 Increased by +21.05% |
| Nov 7, 24 | -0.22 Increased by +68.57% | -0.36 Increased by +38.89% |
| Aug 8, 24 | -0.44 Increased by +41.33% | -0.44 |
| May 14, 24 | -0.48 Increased by +17.24% | -0.54 Increased by +11.11% |
| Mar 26, 24 | -0.56 Increased by +11.02% | -0.79 Increased by +29.04% |
| Nov 7, 23 | -0.70 Decreased by -1.45% | -0.80 Increased by +12.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -18.71 M Increased by +11.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -15.33 M Increased by +34.00% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -14.88 M Increased by +44.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 11.00 M Increased by +N/A% | -10.59 M Increased by +68.23% | Decreased by -96.24% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.07 M Increased by +41.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -23.23 M Increased by +10.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.71 M Increased by +N/A% | -26.93 M Increased by +3.01% | Decreased by -1.58 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -33.33 M Decreased by -31.15% | Decreased by N/A% Decreased by N/A% |